UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/520,022	01/23/2006	Bror Morein	0208/77236/RDK	5079
23432 COOPER & DU	7590 02/20/200 J NHAM. LLP	EXAMINER		
30 Rockefeller		CHEN, CATHERYNE		
20th Floor NEW YORK, N	NY 10112		ART UNIT	PAPER NUMBER
			1655	
			MAIL DATE	DELIVERY MODE
			02/20/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/520,022	MOREIN ET AL.				
Office Action Summary	Examiner	Art Unit				
	CATHERYNE CHEN	1655				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>17 No</u>	ovember 2008					
	action is non-final.					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1,2,5 and 10-14</u> is/are pending in the application.						
4a) Of the above claim(s) <u>14</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) <u>1, 2, 5, 10-13</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)	_					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	4) ☐ Interview Summary Paper No(s)/Mail Da					
Notice of Draftsperson's Patent Drawing Review (P10-948) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal P					
Paper No(s)/Mail Date	6) Other:					

Application/Control Number: 10/520,022 Page 2

Art Unit: 1655

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on Aug. 5, 2008 has been entered.

Election/Restrictions

Applicant's election with traverse of fraction A and C of Quillaja Saponaria in the reply filed on Nov. 17, 2008 is acknowledged. The traversal is on the ground(s) that there is no burden to search all the species. This is not found persuasive because a search of one group is not coextensive with the search of the other groups. Thus, it would be burdensome to search the entire claims.

The requirement is still deemed proper and is therefore made FINAL.

Claim 14 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on Nov. 17, 2008.

Claims 1-2, 5, 10-13 have been examined on the merits.

Application/Control Number: 10/520,022 Page 3

Art Unit: 1655

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the

basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on calculate the data of carellaction for notate in the United States.

sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-2, 5, 10-13 are rejected under 35 U.S.C. 102(b) as being anticipated by Cox et

al. (WO 96/11711).

Cox et al. teaches saponin preparations from the bark of Quillaja saponaria Molina (page

1, lines 4-6) comprising 50-90% by weight of Fraction A of Quil A and from 50-10% by weight

of Fraction C of Quil A (page 3, lines 23-25), where fractions Quil A human (QH) designated

QH-A, QH-C iscoms are purified (page 10, line 19). Preparations of iscom-matrix and protein-

iscoms are made with QH703 or proteins, respectively (page 15, lines 5, 7). The amounts of QH

703 and Quil A confer different immunogenicity (page 16, lines 1-3, 11-13). Preparations of

Quil A, QH-C and mixtures of QH-A and QH-C were used to make iscom matrices for dosing

mice to study the potential immunomodulatory activity of iscoms made from these various

components and mixtures (Example 6). Thus, at least two different saponin fractions of Quillaja

sapnoaria Molina in separate iscom particles have immunomodulating activity.

Therefore, the reference is deemed to anticipate the instant claims above.

Conclusion

No claim is allowed.

Art Unit: 1655

Contact Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Catheryne Chen whose telephone number is 571-272-9947. The

examiner can normally be reached on Monday to Friday, 9-5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Catheryne Chen Examiner Art Unit 1655

/Christopher R. Tate/ Primary Examiner, Art Unit 1655